Displaying drugs 10501 - 10525 of 12564 in total
Ulixertinib
Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity . It is currently in clinical trials for the treatment of a wide range of tumors.
Investigational
Matched Description: … It is currently in clinical trials for the treatment of a wide range of tumors. …
Serabelisib
Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).
Investigational
Matched Description: … investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of ... Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) …
ABT-072
ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C).
Investigational
Matched Description: … Multiple Doses of ABT-072 Used to Treat Hepatitis C). ... Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of …
2X-121
2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP).
Investigational
Matched Description: … 2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and ... Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X …
Bleselumab
Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients).
Investigational
Matched Description: … Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of ... Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant …
Lifastuzumab vedotin
Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
Investigational
Matched Description: … Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of ... Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant …
Zinc glycinate
Glycoprotein marker of gastrointestinal cancer.
Experimental
Matched Description: … Glycoprotein marker of gastrointestinal cancer. …
APG-157
APG-157 consists of zinflavonoids being investigated for the treatment of cancers.
Investigational
Nutraceutical
Matched Description: … APG-157 consists of zinflavonoids being investigated for the treatment of cancers. …
Technetium Tc-99m arcitumomab
Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99. The molecule has a molecular weight of ~54,000 Daltons.
Experimental
Matched Description: … The molecule has a molecular weight of ~54,000 Daltons. ... Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity …
Beta-D-Glucose
A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement.
Experimental
Matched Description: … A primary source of energy for living organisms. ... It is naturally occurring and is found in fruits and other parts of plants in its free state. …
INS 316
INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer. It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.
Investigational
Matched Description: … of lung diseases, including lung cancer. ... INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis …
IMCY-0141
IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves.
Investigational
Matched Description: … multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves. ... MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of …
CNS-5161
CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
Investigational
Matched Description: … CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials ... as a novel compound for the treatment of neuropathic pain. …
R1295
R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.
Investigational
Matched Description: … R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis ... Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid …
OC-1012
OC-1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of mucositis, a serious side effect of chemotherapy and head and neck radiation therapy.
Investigational
Matched Description: … mucositis, a serious side effect of chemotherapy and head and neck radiation therapy. ... 1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of …
Debamestrocel
Debamestrocel consists of autologous mesenchymal stromal cells secreting neurotrophic factors. Debamestrocel is under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Investigational
Matched Description: … Debamestrocel consists of autologous mesenchymal stromal cells secreting neurotrophic factors. ... under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of …
GBR-12783
A selective inhibitor of dopamine uptake.
Investigational
Matched Description: … A selective inhibitor of dopamine uptake.[A252997] …
Besifovir dipivoxil
Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.
Investigational
Matched Description: … The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of ... Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. ... Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of …
Nebicapone
Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg).
Investigational
Matched Description: … of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg). ... Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state ... on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose …
SEP-363856
SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A). SEP-363856 was developed by Sunovion pharmaceuticals....
Investigational
Matched Description: … Additional clinical trials of SEP-363856 are required to confirm the safety and efficacy of this drug ... SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. ... initial clinical study has shown this drug may be effective against both positive and negative symptoms of …
RDEA806
RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
Investigational
Matched Description: … reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of …
PZM21
PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands such as morphine.
Experimental
Matched Description: … receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of ... the respiratory depressant effects characteristic of classical μ-opioid ligands such as morphine. …
PTC299
PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC's GEMS technology by targeting the post-transcriptional processes that regulate VEGF...
Investigational
Matched Description: … PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular ... Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration ... post-transcriptional processes that regulate VEGF formation, and is currently being developed for the treatment of …
QS-21
QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment. It is the leading member of the Stimulon family of adjuvants. As a vaccine additive, it is currently being...
Investigational
Matched Description: … It is the leading member of the Stimulon family of adjuvants. ... As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas …
R-851
R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate the human body's immnune system to attack virus-infected cells and tumor cells. It is expected to be topical treatment for cervical displasia and cervical high-risk human papillomavirus (HPV), the sexually...
Investigational
Matched Description: … R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate ... cervical high-risk human papillomavirus (HPV), the sexually transmitted virus that causes most cases of …
Displaying drugs 10501 - 10525 of 12564 in total